Article Text

PDF
E355G mutation appearing in a patient with e19a2 chronic myeloid leukaemia resistant to imatinib
  1. Ayda Bennour1,
  2. Nathalie Beaufils2,
  3. Halima Sennana1,
  4. Balkis Meddeb3,
  5. Ali Saad1,
  6. Jean Gabert2
  1. 1Department of Cytogenetics Molecular Genetics and Reproductive Biology, Farhat Hached University Teaching Hospital, Sousse, Tunisia
  2. 2Laboratory of Biochemistry and Molecular Biology, Nord Hospital, Marseille, France
  3. 3Department of Clinical Hematology Aziza Othmana Hospital, Tunis, Tunisia
  1. Correspondence to Ayda Bennour, Department of Cytogenetics Molecular Genetics and Reproductive Biology, Farhat Hached University Teaching Hospital, Sousse, Tunisia; aydabennour{at}yahoo.fr

Abstract

The development of imatinib is a milestone in the treatment of chronic myeloid leukaemia (CML), and its therapeutic effect has been extensively investigated in patients with CML who carry M-bcr and m-bcr BCR–ABL fusion transcripts. However, knowledge about its therapeutic effect on patients with CML who have the rare BCR–ABL fusion transcript e19a2 (μ-bcr) remains sparse. This report describes a patient with Philadelphia-positive chronic myeloid leukaemia with e19a2 rearrangement, in whom E355G mutation had been acquired. The patient was resistant to imatinib treatment based on conventional cytogenetic and fluorescence in situ hybridisation analysis.

  • Chronic myeloid leukaemia
  • cytogenetics
  • haemato-oncology
  • molecular oncology

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval Ethics approval was obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.